Apratyramide therapeutic agents and methods of treatment
The invention is directed towards Apratyramide linear depsipeptide compounds, pharmaceutical compositions thereof, and methods of affecting wound healing, and methods of affecting the biological processes involved in wound healing (e.g., inflammation, cell proliferation, tissue granulation, remodeling of scar tissue, etc.).
1. A compound according to the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof.
2. The compound or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof of claim 1 , wherein the compound is:
3. A pharmaceutical composition comprising the compound of claim 1 , or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
4. A topical pharmaceutical composition comprising the compound of claim 1 , or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof, and a pharmaceutically acceptable topical carrier.
5. A method of treating a subject suffering from or susceptible to a wound, comprising administering to said subject in need thereof, an effective amount of a compound of claim 1 , or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof.
6. The method of claim 5 , wherein the wound is a chronic wound.
7. The method of claim 5 , wherein the wound is a diabetic foot ulcer [DFU], pressure ulcer [PU], or chronic venous leg ulcer [VU].
8. A method of treating a subject suffering from or susceptible to a disorder or disease mediated by VEGF, comprising administering to said subject in need thereof, an effective amount of a compound of claim 1 , or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof, wherein the disorder or disease is a wound.
9. The method of claim 8 , wherein the disorder or disease is mediated by VEGF-A.
10. The method of claim 8 , wherein the wound is a chronic wound.
11. The method of claim 8 , wherein the wound is a diabetic foot ulcer [DFU], pressure ulcer [PU], or chronic venous leg ulcer [VU].
12. A method of inducing VEGF expression in a subject, comprising administering to said subject an effective amount of a compound of claim 1 , or pharmaceutically acceptable salt, solvate, hydrate, prodrug, or stereoisomer thereof.